[ad_1]
China's health regulator says all national medical institutions must cooperate with the authorities and not use the blood and heart drug from valsartan manufactured by Zhejiang Huahai Pharmaceutical Co. Ltd. which could pose cancer risks. that he was reminiscent of the drug valsartan sold in the United States after the European Medicines Agency found that it was tainted with a cancer-related impurity.
In a notice posted on his website Monday, the Chinese National Commission of Health and Family Planning said the recalled drug, commonly used to treat patients with high blood pressure, should not be used to diagnosis and treatment of diseases.
European regulators said the problem was related to the changes introduced in the company's manufacturing processes in 2012, suggesting that many patients may have been at risk for cancer.
The drug has already been withdrawn in the United States and Huahai completed Sunday the withdrawal in China of raw materials used to make the drug, said Sunday the Chinese Ministry of Foreign Affairs and the Chinese Medicines Regulator (19659003). days. On Sunday, police announced that she was asking for arrest warrants against 18 people at Changsheng Bio-Technology Co Ltd., a vaccine manufacturer that had falsified data and sold ineffective vaccines for children
. On Monday, the tracking index of major Chinese health care enterprises fell 3 percent, putting it on the way to a third consecutive day of losses.
The Chinese regulator also said that there were six local companies using valsartan. Five of these companies had products on the market and have since issued reminders, he added.
Originally, China ordered the end of the use of recalled drugs
Source link
